Recurrent Breast Cancer — A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
Citation(s)
A Phase II Study of Foretinib in Patients With Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer